Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Pembrolizumab with bevacizumab was well tolerated and demonstrated substantial activity in patients with untreated MBM with promising OS, justifying further evaluation of this regimen.
Authors
- Harriet M. Kluger (ORCID: https://orcid.org/0000-0002-4932-9873)
- Adebowale Adeniran (ORCID: https://orcid.org/0000-0001-9820-632X)
- Thuy Tran (ORCID: https://orcid.org/0000-0002-6244-7575)
- Upendra P. Hegde (ORCID: https://orcid.org/0000-0001-5732-1401)
- Zeynep Eroglu (ORCID: https://orcid.org/0000-0002-2307-7030)
- Gail D. Anderson (ORCID: https://orcid.org/0000-0002-5112-5626)
- Sarah B. Goldberg (ORCID: https://orcid.org/0000-0002-0920-1381)
- Amit Mahajan (ORCID: https://orcid.org/0000-0002-6532-2209)
- Peter Forsyth
- Joseph Markowitz (ORCID: https://orcid.org/0000-0003-2490-5464)
- Justine V. Cohen (ORCID: https://orcid.org/0000-0003-4803-9230)
- Veronica Chiang (ORCID: https://orcid.org/0000-0003-1882-3876)
- Nikhil I. Khushalani (ORCID: https://orcid.org/0000-0002-3636-4143)
- Barbara Johnson (ORCID: https://orcid.org/0000-0002-4374-4996)
- Sarah A. Weiss (ORCID: https://orcid.org/0000-0002-1106-7089)
- Lucia B. Jilaveanu (ORCID: https://orcid.org/0000-0001-8900-5083)
- Wei Wei (ORCID: https://orcid.org/0000-0003-1263-5620)
- Matthew R Austin
- Dijana Djureinovic (ORCID: https://orcid.org/0000-0002-1852-5409)
- Cecily Piteo
- Mario Sznol (ORCID: https://orcid.org/0000-0003-4137-9662)
Institutions
- Rutgers, The State University of New Jersey (US)
- University of Connecticut (US)
- Moffitt Cancer Center (US)
- Yale University (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1200/jco-24-02219
- Citations
- 8
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 8.36